NLRC5 and neoplasm: Costaining with NLRC5 and CD20 antibodies confirmed that the decrease in NLRC5 seen in aberrant sections is attributed to B‐cells in these tumours (mean ratio 0.16% vs 0.35% in WT sections; P < .01, Figure 6C).